We hypothesised that cardiovascular changes already exist in children with cystic fibrosis compared with healthy control children. Therefore, we will evaluate the cardiovascular system in a group of children with cystic fibrosis compared with…
ID
Source
Brief title
Condition
- Myocardial disorders
- Congenital respiratory tract disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameters are the echocardiographic measurements of the
cardiovascular system (diastolic function of the right and left ventricle).
Secondary outcome
Secundary study outcome is arterial stiffness (pulse wave velocity) and the
respiratory system (the lung function measurement).
Background summary
The life-expectancy of patients with cystic fibrosis is increasing and the
proportion of patients with cystic fibrosis who are middle-aged is increasing.
Therefore, there is a need to focus on extra-pulmonary comorbidities that
affect the length and quality of life in the adult stage of the disease.1
Several studies showed that adult patients with cystic fibrosis have a
decreased systolic and diastolic function of the heart (especially the right
ventricle) and an increased arterial stiffness compared to healthy controls. It
is unknown when these changes appear.
By our knowledge, the cardiovascular system has not been studied in children
with cystic fibrosis. It is important with regard to prevention of
cardiovascular disease in cystic fibrosis patients to get a better
understanding of the development of this process. If cardiovascular changes
already exist in early childhood, it could lead to an earlier screening for
cardiovascular disease in these patients.
Study objective
We hypothesised that cardiovascular changes already exist in children with
cystic fibrosis compared with healthy control children. Therefore, we will
evaluate the cardiovascular system in a group of children with cystic fibrosis
compared with control subjects.
Study design
Cross-sectional design
Study burden and risks
There are no risks associated with participation in this study. There is no
benefit for the children in participating to this study and participation is
completely voluntary.
Lundlaan 6
Utrecht 3508 AB
NL
Lundlaan 6
Utrecht 3508 AB
NL
Listed location countries
Age
Inclusion criteria
Children with cystic fibrosis:
• Aged 3-12 years
• Who visit the pediatric pulmonology department for their regular control visit;Health controls
• Aged 3-12 year
• Participating in the WHISTLER study
Exclusion criteria
Children with cystic fibrosis:
• Children with a history of a heart defect will be excluded from this study.;Healthy controls
• Children with a history of a heart defect will be excluded from this study.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL39258.041.12 |